Topic: intranasal administration

Several therapeutic targets have been identified to counteract the cognitive decline of Alzheimer's disease (AD). One of the recent approaches, which takes account the multifactorial origin of AD, is pleiotropic drugs. Multi-targeted directed ligands are designed to target different molecular causes involved in the pathogenesis of AD. A novel compound, acting as a prodrug and able of both selectively inhibiting butyrylcholinesterase and secondarily interacting with serotonin subtype 4 receptor, has therefore been developed. The first step of the project was to assess pharmacological screening

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective death of motoneurons (MNs). Our previous results revealed that intravenous administration of mesenchymal stem cells (MSCs) improved different pathological features in SOD1G93A ALS mice. We hypothesised that the beneficial effect could be mediated by paracrine activity of extracellular vesicles (EVs) secreted by MSCs shuttling microRNAs . Subsequently, we studied in-vitro the activity of MSCs-derived EVs on spinal cord astrocytes of symptomatic SOD1G93A mice. The results demonstrated that 24h in-